Last updated on March 2018

Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients


Brief description of study

This is a clinical trial comparing the immunosuppressive treatment determined according to two biomarkers, donor-specific IFN- ELISPOT and Mismatch of HLA between donor and recipient, in patients undergoing low immunological risk live donor kidney transplantation

Detailed Study Description

This is a national multicenter clinical trial, controlled, randomized, stratified, parallel groups, and without masking.

This is a prospective intervention study in which two strategies for determining immunosuppressive treatment in kidney transplant patients from a live donor with low immunological risk are compared according to solid phase antibody detection techniques (cPRA 0% and isolated negative antigen) and crossmatch by negative cytotoxicity. Patients are randomized in a 1: 1 ratio to receive one of two immunosuppressive treatment strategies.

Clinical Study Identifier: NCT03465397

Contact Investigators or Research Sites near you

Start Over

ORIOL BESTARD, DR

Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
  Connect »

LAURA CAÑAS

Hospital Universitari Germans Trias I Pujol
Badalona, Spain
  Connect »

CARME FACUNDO, DR

Fundaci Puigvert
Barcelona, Spain
  Connect »

FRITZ DIEKMANN, DR

Hospital Clinic
Barcelona, Spain
  Connect »

MARTA CRESPO, DR

Hospital Del Mar
Barcelona, Spain
  Connect »

FRANCESC MORESO, DR

Hospital Universitari Vall D'Hebr n
Barcelona, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.